Umbralisib Linked to Fewer Side Effects in Advanced Lymphoma and Leukemia Patients, Data Show

Pooled analysis data out of the 2018 Congress of the European Hematology Association demonstrate that the PI3Kδ inhibitor umbralisib has a better long-term safety profile than other PI3Kδ inhibitors, including idelalisib and duvelisib in patients with relapsed/refractory lymphoid malignancies.

Lymphoma News Today